Hikma Pharmaceuticals Plc Director/PDMR Shareholding (9336H)

TIDMHIK

RNS Number : 9336H

Hikma Pharmaceuticals Plc

19 March 2015

Hikma Pharmaceuticals PLC - Vesting of 2012 LTIP

LONDON, 19 March 2015: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) announces that the following Persons Discharging Managerial Responsibility ("PDMR") have received shares as a result of the vesting of their conditional share awards on 19 March 2015 under the 2005 Long Term Incentive Plan ("LTIP"). These awards were automatically exercised by operation of the conditional award and vesting process. The exercise price under the LTIP is GBPnil. The persons concerned have retained all the shares exercised.

In accordance with DTR 3.1.2R and s.793 of the Companies Act 2006, Hikma announces that the following transactions took place in London over the Company's Ordinary Shares of 10p each as detailed below.

 
 
 Bassam          Vesting of   46,300         19 March   GBP22.26   Nil       500,390 
  Kanaan          LTIP 2012                   2015 
                               (0.02% ISC)                                    (0.25% ISC) 
                -----------  -------------  ---------  ---------  --------  ------------------ 
 Michael         Vesting of   43,800         19 March   GBP22.26   Nil       119,960 
  Raya            LTIP 2012                   2015 
                               (0.02% ISC)                                    (0.06% ISC) 
                -----------  -------------  ---------  ---------  --------  ------------------ 
 Riad Mishlawi   Vesting of   20,700         19 March   GBP22.26   Nil       100,027 
                  LTIP 2012                   2015 
                               (0.01% ISC)                                    (0.05% ISC) 
                -----------  -------------  ---------  ---------  --------  ------------------ 
 Khalid          Vesting of   26,000         19 March   GBP22.26   Nil       222,858 
  Nabilsi         LTIP 2012                   2015 
                               (0.01% ISC)                                    (0.11% ISC) 
                -----------  -------------  ---------  ---------  --------  ------------------ 
 
   "ISC" = Issued Share Capital of Hikma which is 198,879,939 
   Ordinary Shares following the release of the LTIP 2012

- ENDS -

Enquiries

Peter Speirs +44 20 7399 2760

Company Secretary, Hikma Pharmaceuticals PLC

About Hikma

Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group focused on developing, manufacturing and marketing a broad range of both branded and non-branded generic and in-licensed products. Hikma's operations are conducted through three businesses: "Branded", "Injectables" and "Generics" based primarily in the Middle East and North Africa ("MENA") region, where it is a market leader, the United States and Europe. In 2014, Hikma achieved revenues of $1,489 million and profit attributable to shareholders of $278 million.

This information is provided by RNS

The company news service from the London Stock Exchange

END

RDSBXGDXSSBBGUC

Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024